Hepatoprotective effects of Orthosiphon stamineus extract on thioacetamide-induced liver cirrhosis in rats by Alshawsh, Mohammed A. et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 103039, 6 pages
doi:10.1155/2011/103039
Research Article
Hepatoprotective Effects of Orthosiphon stamineus Extract on
Thioacetamide-Induced Liver Cirrhosis in Rats
Mohammed A. Alshawsh, Mahmood Ameen Abdulla, Salmah Ismail, and Zahra A. Amin
Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia
Correspondence should be addressed to Mohammed A. Alshawsh, alshaweshmam@yahoo.com
Received 18 October 2010; Revised 4 January 2011; Accepted 2 February 2011
Copyright © 2011 Mohammed A. Alshawsh et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Orthosiphon stamineus as medicinal plant is commonly used in Malaysia for treatment of hepatitis and jaundice; in this study, the
ethanol extracts were applied to evaluate the hepatoprotective eﬀects in a thioacetamide-induced hepatotoxic model in Sprague
Dawley rats. Five groups of adult rats were arranged as follows: Group 1 (normal control group), Group 2 Thioacetamide (TAA) as
positive control (hepatotoxic group), Group 3 Silymarin as a well-known standard drug (hepatoprotective group), and Groups 4
and 5 as high and low dose (treatment groups). After 60-day treatment, all rats were sacrificed. The hepatotoxic group showed
a coarse granulation on the liver surface when compared to the smooth aspect observed on the liver surface of the other groups.
Histopathological study confirmed the result; moreover, there was a significant increase in serum liver biochemical parameters
(ALT, AST, ALP, and Bilirubin) and the level of liver Malondialdehyde (MDA), accompanied by a significant decrease in the level
of total protein and Albumin in the TAA control group when compared with that of the normal group. The high-dose treatment
group (200mg/kg) significantly restored the elevated liver function enzymes near to normal. This study revealed that 200mg/kg
extracts of O. stamineus exerted a hepatoprotective eﬀect.
1. Introduction
The liver is an important organ responsible for the metabo-
lism, bile secretion, elimination of many substances, blood
detoxifications, synthesizes, and regulation of essential hor-
mones. Liver diseases have become a worldwide problem
and are associated with significant morbidity and mortality.
The principal causative factors for the liver diseases in
developed countries are excessive alcohol consumption, and
viral-induced chronic liver diseases while in the developing
countries the most frequent causes are environmental toxins,
parasitic disease, hepatitis B and C viruses, and hepato-
toxic drugs (certain antibiotics, chemotherapeutic agents,
high doses of paracetamol, carbon tetrachloride (CCL4),
thioacetamide (TAA), etc.). Chronic liver cirrhosis and drug
induced liver injury accounting the ninth leading cause of
death in western and developing countries [1]. In the absence
of reliable hepatoprotective drugs in modern medicine, a
large number of herbal preparations have become increas-
ingly popular for the treatment of liver disorders [2].
A number of herbals show promising activity, including
Silymarin for liver cirrhosis, Phyllantus amarus in chronic
hepatitis B, glycyrrhizin to treat chronic viral hepatitis, and
some herbal combinations from China and Japan that have
been scientifically proven for treatment of liver diseases
[3]. Silymarin, a flavonolignan from “milk thistle” Silybum
marianum, is widely used for hepatoprotection. Silymarin
oﬀers good protection in diﬀerent toxic models of induced
liver cirrhosis experiments by using laboratory animals.
Orthosiphon stamineus Benth (Family: Lamiaceae),
named Misai kucing (Malaysia), kumis kucing (Indonesia),
and Java tea (Europe), this is native plant to South East
Asia [4]. O. stamineus has been widely used in Malaysia for
treating kidney problems, fever, hypertension, gout, diabetes,
hepatitis, and jaundice [5, 6]. The literature review shows
that this plant contains phenolic compounds and flavonoids.
More than twenty phenolic compounds were isolated from
O. stamineus, the most important constituents are nine
lipophilic flavones, two flavonol glycosides, and nine caﬀeic
acid derivatives [7]. The well-known chemical constituents
of O. stamineus are caﬀeic acid, cirrchoric acid, diter-
penes, orthosiphols, monoterpenes, triterpenes, saponins,
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hexoses, organic acids, rosmarinic acids, sinensetin, eupa-
torin, and 3′-hydroxyl-5,6,7,4′-tetramethoxyflavone [8–10].
O. stamineus has been proven using animal models to treat
diabetes mellitus and improving lipid profile in diabetic
rats [11], kidney problem diuretic and hypouricemic eﬀects
in rats [12], as anti-inflammatory [13], for the treatment
of hypertension [14], and antipyretic activity [15]. The
experimental induction of liver cirrhosis by long exposure
of Thioacetamide results in histological and biochemical
changes similar to that of human liver cirrhosis [16]. The
TAA model is more reliable and easy for induced liver
cirrhosis than the CCl4 model [17]. This study was carried
out to assess the hepatoprotective activity of O. stamineus
against thioacetamide-induced hepatotoxicity in rats to
prove scientifically the traditional use of this plant against
liver disorders.
2. Materials and Methods
2.1. Plant Materials and Chemicals. O. stamineus plant leaves
were obtained from the Ethno Resource Sdn Bhd. The
plant was identified, and voucher specimen was kept in our
laboratory for future references. The dried and powdered
leaves (100 gm) were extracted with 900mL of 95% ethanol
for 48 hour, and the ethanol extract was filtered and
evaporated under low pressure by using Buchi-type rotary
evaporator to give the crude-dried extract. The percentage
yield of ethanol extracts was found to be 8.1% (w/w). The
dry extract was then dissolved in Tween 20 (10% w/v) and
administered orally to rats in concentrations of 100 and
200mg/kg body weight.
Thioacetamide from (Sigma-Aldrich, Switzerland) and
all other chemicals used were of analytical grade and pur-
chased mostly from Sigma-Aldrich and Fisher. The chemical
was dissolved in sterile distilled water and injected intraperi-
toneally to the rats in concentrations of 200mg/kg body
weight [18]. Silymarin (International Laboratory, USA) as
a standard drug and was dissolved in Tween 20 (10% w/v)
and orally administered to rats in concentrations of 50mg/kg
body weight [19].
2.2. Total Phenolic and Flavonoids Determination. The O.
stamineus extract was evaluated for their total phenolic
content by using Folin-Ciocalteu reagent and was calculated
as gallic acid equivalents in mg (GAE)/g of extract according
to Folin-Denis colorimetric method [20]. However, the total
flavonoids was determined by using the aluminium chloride
colorimetric method and expressed as quercetin equivalents
in mg (QE)/g of extract as described by Dowd [21]. Both
assays were carried out in triplicate.
2.3. Animals. Adult male healthy Sprague Dawley (SD) rats
weighing 200–250 gm were obtained from Animal House
Unit, Faculty of Medicine, University of Malaya, Malaysia.
They were kept in wire-bottomed cages at 25 ± 3◦C
temperature, 50–60% humidity, and a 12 h light-dark cycle
for at least a week before the experiment. They were
maintained at standard housing conditions and free access
to standard diet and water ad libitum during the experiment.
The experimental protocol was approved by Animal Ethics
Committee; with an ethic no. (PM 28/08/2009/MAA (R).
Throughout the experiments, all criteria of taking care of
animals prepared by the National Academy of Sciences and
outlined in the “Guide for the Care and Use of laboratory
Animals” were applied.
2.4. Experimental Design. The animals were randomly
divided into five groups of eight rats each and treated as
follows.
Group 1. 10% Tween 20 (5mL/kg, po) daily for 2 months
+ sterile distilled water (1mL/kg, i.p) thrice weekly for 2
months (normal control group).
Group 2. 10% Tween 20 (5mL/kg, po) daily for 2 months
+ TAA (200mg/kg, i.p) thrice weekly for 2 months (positive
control hepatotoxic group).
Group 3. Silymarin (50mg/kg, po) daily for 2 months + TAA
(200mg/kg, i.p) thrice weekly for 2 months (well known
standard drug hepatoprotective group).
Group 4. O. stamineus (200mg/kg, po) daily for 2 months +
TAA (200mg/kg, i.p) thrice weekly for 2 months (treatment
group, high dose).
Group 5. O. stamineus (100mg/kg, po) daily for 2 months +
TAA (200mg/kg, i.p) thrice weekly for 2 months (treatment
group, low dose).
Body weights of all animals were measured every week.
All rats were sacrificed 24 hours after last treatment and
overnight fasting under diethyl ether anesthesia. Blood
samples were collected; serum was separated for assay of
the liver biomarker. The liver and spleen were harvested,
washed in normal saline, blotted with filter paper, and
weighed. Gross examination was conducted to examine of
any abnormalities developed in the organs. The liver of
all animals was subsequently subjected to histopathological
examination in a blinded fashion.
2.5. Biochemical and Histopathological Examination. The
collected blood samples were separated at 2500 rpm for
15 minutes after been completely become clotted. Serum
for assay of the liver biomarkers such as Aspartate amino-
transferase (AST), Alanine aminotransferase (ALT), Alka-
line phosphatase (ALP), Bilirubin, Total protein (TP), and
Albumin was assayed spectrophotometrically by standard
automated techniques according to the procedures described
by the manufacturers in Central Diagnostic Laboratory, Uni-
versity of Malaya Medical Centre. The Liver was sliced and
pieces were fixed in 10% buﬀered formaldehyde solution for
histological study. The fixed tissues were processed by auto-
mated tissue processing machine. Tissues were embedded in
paraﬃn wax by conventional methods. Sections of 5 µm in
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thickness were prepared and then stained with hematoxylin-
eosin (HE). After that the sections were observed under the
microscope for histopathological changes, and their pho-
tomicrographs were captured.
2.6. Estimation of Malondialdehyde (MDA) in Liver Tissue.
Liver samples were washed immediately with ice-cold saline
to remove as much blood as possible. Liver homogenates
(10% w/v) were prepared in a cold 50mM potassium
phosphate buﬀer (pH 7.4) using homogenizer in ice. The cell
debris was removed by centrifugation at 4500 rpm for 15 at
4◦C using refrigerated centrifuge. The supernatant was used
for the estimation of Malondialdehyde (MDA) level by using
(Cayman Chemical Company, U.S.A) kit.
2.7. Statistical Analysis. The statistical significance was
assessed using one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni’s multiple comparison test. All values
were expressed as mean ± S.E.M., and a value of P < .05 was
considered significant as compared to the respective control
group using SPSS programme for windows version 18 (SPSS
Inc. Chicago, IL, USA).
3. Results
3.1. Body, Liver, and Spleen Weight. Before the treatment
was started the rats weighed 200–250 g and after two
months animals of normal, HD, LD, and Silymarin groups
reached average body weights of 254.9, 232.7, 263.3, and
257.0 g, respectively. However, TAA positive control group
the average body weight was decreased to 202.0 g but without
a significant diﬀerence compared to the normal control
group. There was no significant diﬀerence between the
groups but long-term taken of TAA led to significant increase
of the liver weight compared to normal rats. Values of mean
relative liver weight (LW/BW) percent showed a significant
diﬀerence between treated groups compared to TAA group
(Table 1).
3.2. Biochemical and Antioxidant Parameters. Long-term
taken of TAA led to significant increase of biochemical
markers ALT, AST, ALP, Bilirubin, and MDA level, while
significantly decreased total protein and albumin compared
to the normal control group, indicating acute hepatocytes
damage. Treatment of animals with O. stamineus extracts
and Silymarin significantly reduced the level of liver function
biomarker (ALT, AST, ALP, and bilirubin) and antioxidant
parameter (MDA), in addition significantly increased in
total protein and albumin comparing with the thioacetamide
group. The toxic eﬀect of TAA was controlled in the rats
treated with ethanolic extracts (100mg/kg and 200mg/kg)
and that is approved by restored of the levels of the
liver biomarker. At a dose of 100mg/kg, the eﬀect was
only marginal, whereas at the higher dose (200mg/kg) the
extract eﬀectively prevented the TAA-induced liver damage
(Table 2). The ethanol extracts of O. stamineus significantly
restored the altered liver parameters and made it more
resemble to that of standard drug Silymarin (50mg/kg).
Moreover, O. stamineus extract at 200mg/kg (P < .05)
demonstrated the most potent eﬀect in protecting rats
against TAA-induced liver damage, as evidenced by the
reduced in all enzyme levels of AST, ALT, and ALP and
increased in total protein and albumin levels compared to
the control. On the other hand, the total phenolic contents
were 294.3 ± 0.005mg (Gallic acid equivalents) per g of
extracts (standard curve equation: y = 0.0013x + 0.0032,
R
2 = 0.987). At the same time, flavonoids were 171.4 ±
0.006mg (Quercetin equivalents) per g of extracts (standard
curve equation: y = 0.0040x + 0.0085, R2 = 0.991) and
a ratio flavonoids/phenolics of 0.58. Thus, phenolic com-
pounds were the predominant antioxidant components in
O. stamineus extracts, which lead to more potent radical
scavenging eﬀect.
3.3. Histopathology Examination. Histopathological exami-
nation of liver sections of the normal group showed regular
cellular architecture with distinct hepatic cells, sinusoidal
spaces, and a central vein. The hepatocytes are polygonal
cells with well preserved cytoplasm, nucleus with prominent
nuclei. On the other hand, in the hepatotoxic positive control
group, histological examination showed loss of architecture,
inflammation, and congestion with cytoplasmic vacuolation,
fatty change, sinusoidal dilatation, centrilobular necrosis,
and displayed bundles of collagen surrounding the lobules,
which resulted in huge fibrous septa and distorted tissue
architecture. In O. stamineus-treated animals, liver sections
showed mild inflammation and mild necrosis of hepato-
cytes with mild cytoplasmic vacuolation, and mostly no
visible changes observed. Histopathological examination also
showed good recovery of thioacetamide-induced necrosis
by ethanolic extracts as compared to Silymarin. Animals
treated with the low dose showed regeneration of hepatocytes
surrounded by septa of fibrous tissue with a significant
increase in bile ductules, fat storing cells, and Kupﬀer cells.
Animals treated with the higher dose of plant extract showed
remarkable histological regeneration compared to those of
the LD group. They showed nearly ordinary patterns with
an increase normal hepatocytes parenchyma and a reduced
development of fibrous septa and lymphocyte infiltration.
Results of the gross and histopathological examination are
shown in the figures (Figure 1).
4. Discussion
Toxic injury occurs in the liver more often than that
in any other organ. When a drug is used widely, drug-
induced liver injury has become a serious health problem
in contemporary society, then research on the mechanism
of drug-induced liver injury is very useful in therapy
and prevention of drug-induced liver injury [22]. Thioac-
etamide is known hepatotoxic, which produces hepatic
necrosis in high doses by producing free radicals during
TAA metabolism resulting in oxidative stress mediated
acute hepatitis and induces apoptosis of hepatocytes in
the liver [23]. It has been reported that long-term taken
of TAA induced cirrhosis in rats; on account of this, it
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Table 1: The body, liver, and spleen weight of rats after two-month treatments.
Animal group
Body weight (g)
(BW)
Liver weight (g)
(LW)
LW/BW (%)
Spleen weight (g)
(SW)
SW/BW (%)
Normal control 254.9 ± 28.69 6.71 ± 0.64 2.71 ± 0.18 0.47 ± 0.08 0.18 ± 0.02
TAA control (hepatotoxic group) 202.0 ± 19.10 11.00 ± 1.11∗a 5.43 ± 0.17∗a 0.52 ± 0.07 0.26 ± 0.03
HD 200mg/kg (treatment group) 232.7 ± 16.12 10.43 ± 0.69 4.50 ± 0.19∗b 0.54 ± 0.04 0.23 ± 0.01
LD 100mg/kg (treatment group) 263.3 ± 8.53 10.43 ± 0.72 3.94 ± 0.16∗∗c 0.55 ± 0.03 0.21 ± 0.01
Silymarin 50mg/kg
(hepatoprotective group)
257.0 ± 21.97 7.71 ± 2.78 2.94 ± 0.13∗∗c 0.53 ± 0.07 0.20 ± 0.01
All values are expressed as mean ± S.E.M. Means with diﬀerent superscripts are significantly diﬀerent.
aP < .05 versus Normal control group, bP < .05 versus TAA control group, and cP < .01 versus TAA control group.
Table 2: Eﬀect of TAA, Silymarin, and O. stamineus ethanolic extract on biochemical parameters in thioacetamide-Induced liver cirrhosis
rats.
Animal group ALT (IU/L) AST (IU/L) ALP (IU/L) Bilirubin (mg/dl) T.Protein (g/l) Albumin (g/l) MDA nmol/mL
Normal control 64.9 ± 4.19a 164.4 ± 10.74a 109.6 ± 9.80a 1.86 ± 0.1a 74.3 ± 1.15a 12.1 ± 0.51a 38.7 ± 2.6a
TAA Control 213.3 ± 25.98d 372.6 ± 29.98d 435.8 ± 29.78d 8.7 ± 0.57d 60.7 ± 0.97d 8.3 ± 0.57d 107.1 ± 3.7d
HD 200mg/kg 95.7 ± 9.35b 228.6 ± 14.10b 289.0 ± 14.23c 4.8 ± 0.59b 68.0 ± 2.06c 11.1 ± 0.63c 45.3 ± 3.5b
LD 100mg/kg 108.0 ± 11.15c 253.4 ± 18.67c 383.6 ± 20.89 6.4 ± 0.72c 64.6 ± 1.29 9.3 ± 0.36 72.6 ± 3.9c
Silymarin
50mg/kg
70.4 ± 5.60b 171.6 ± 10.19b 139.4 ± 9.54b 3.0 ± 0.31b 70.9 ± 0.91b 11.7 ± 0.68b 40.3 ± 2.8b
All values are expressed as mean ± S.E.M. of eight rats in each group. Values not sharing a common superscript diﬀer significantly, ∗P < .05. ALT: alanine
aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, and MDA: malondialdehyde.
is proven that thioacetamide through cytochrome p-450
pathway is converted into a highly toxic metabolite N-acetyl-
p-benzoquinone imine (NAPBI). Meanwhile, (NAPBI) is
accompanied with glutathione and excreted in the urine
as conjugates. The acute hepatic necrosis induced by TAA,
which activates cytochrome p450 and produces a highly
reactive NAPBQI that, by the way, combines with sulpha-
hydryl groups of proteins and causes a rapid reduction of
intracellular glutathione. Therefore, increases the oxygen free
radical causing an oxidative stress and initiates apoptosis;
consequently, the elevated liver enzymes (ALT, AST) are an
indicator of cellular liver necrosis [24]. In addition, TAA
interferes with the movement of RNA from the nucleus to
the cytoplasm which may cause membrane injury resulting
in a rise in serum liver markers [25]. TAA toxic metabolite
free radicals induced oxidative stress in the hepatic cells. It is
responsible for many changes occur for hepatocytes such as
an increase in nuclear volume and enlargement of nucleoli,
cell permeability changes, rise in intracellular concentration
of Ca++, and eﬀects on mitochondrial activity, which leads
to cell death [19].
Liver damage is associated with cellular necrosis,
increases in tissue lipid peroxidation as MDA and level
caused by oxidative stress and depletion in the tissue GSH
levels. Moreover, serum levels of liver function parameters
like ALT, AST, bilirubin, and alkaline phosphatase are ele-
vated. The mechanism of liver fibrosis is not understood, but
no doubt that oxidative stress and reactive oxygen species
(ROS) play an important role in pathological changes in
the liver. In this study, TAA administration for eight weeks
led to induced liver fibrosis, which has been proven by the
significantly diﬀerence of biochemical markers between the
TAA control and normal control groups. At the same time,
the hepatoprotective eﬀect exhibited by O. stamineus at dose
200mg/kg was comparable to Silymarin at dose 50mg/kg in
TAA-induced liver injury rats. Treatment with the ethanolic
extracts of O. stamineus leaves (200mg/kg) has accelerated
the return of the altered levels of liver function enzyme and to
the near normal profile. The abnormal reconstruction of the
lobular architecture, the appearance of widespread fibrosis in
addition, nodular lesions of the hepatic parenchyma are the
main characteristics of liver cirrhosis [26]. Our histological
findings prove that the ethanol extracts of O. stamineus
aﬀected the recovery of liver structure in TAA-induced liver
cirrhosis rats. Indeed, there was remarkable reduction in
fibrosis extent and a decrease of stellate infiltration in rats
treated with plant extract compared to control TAA group.
Histological studies confirmed the hepatoprotective eﬀect of
O. stamineus ethanolic extract. TAA treated rat liver sections
showed fatty degeneration of hepatocytes and necrosis of
cells. The extract treatment (200mg/kg) almost normalized
these eﬀects in the histoarchitecture of liver. Furthermore,
the severe fatty changes in the livers of rats caused by
TAA were treated in the HD treatment groups. Therefore,
from this study the ethanol extracts of O. stamineus could
be a hepatoprotective against thioacetamide induced liver
damage in rats.
The antioxidant capabilities of the phenolic compounds
are important for the human body to destroy the free radicals
that exist in our body. Many of the polyphenols such as
flavonoids have been identified as powerful antioxidants;
moreover, play a significant role in the treatment of many
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Figure 1: Eﬀect of TAA, Silymarin, and 200mg/kg O. stamineus ethanolic extract on liver gross and histology in TAA-Induced liver cirrhosis
rats after two-month treatments. Eight animals of each group were investigated.
diseases, including liver cirrhosis [27]. On the other hand,
there was a study on the eﬀect of Silybum marianum and
Cichorium intybus extracts on liver cells suggested that
hepatoprotective action due to the presence of flavonoids and
their antioxidant eﬀects [28].O. stamineus has been reported
to possess antioxidant activity; furthermore, the extracts
exhibited significant radical-scavenging activity probably
due to the higher concentration of caﬀeic acid derivatives,
especially rosmarinic acid [9]. By the way, Akowuah also
found that the O. stamineus extract antioxidative potency
was higher than a synthetic antioxidant butylated hydroxy-
lanisole (BHA) and almost equal to that of pure quercetin
[29]. Similarly, the extract show increase in activities of
antioxidant enzymes such as CAT and SOD [30]. In this
study, reduced lipid peroxidation was revealed by a signifi-
cant decrease in MDA level in groups treated with ethanol
extracts. The results of the hepatoprotective eﬀects of this
extracts can be due to the presence of the great amount of
phenolic and flavonoids compounds and their antioxidant
eﬀects besides the free radical scavenging property of this
plant. Likewise, the hepatoprotective activity of the extract
could be due to neutralization of the toxic compounds
produced by converting TAA to a highly toxic metabolite
during cytochrome p-450 pathway as mentioned above. On
account of this O. stamineus extract, it has been reported
recently to aﬀect cytochrome p450 enzyme system through
its inhibition. Consequently, the toxic metabolite of TAA is
aﬀected by the O. stamineus extract that might lead to reduce
the progress of liver necrosis [31].
In conclusion, this study showed that O. stamineus
ethanol extracts have hepatoprotective eﬀects that were
proven by biochemical and histopathological analysis.
Accordingly, the plant extracts could be an eﬀective herbal
for chemical-induced hepatic damage although this finding
needs further study to know the active constituents appear-
ing to protect rat liver against cirrhosis.
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